In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series A for Pevion Biotech results in CHF35mm

Executive Summary

Pevion Biotech (vaccines for infectious diseases and cancer) raised CHF35mm ($29.3mm) through its Series A financing led by first-time backer BZ Bank Aktiengesellschaft. Other new investors BB Biotech Ventures and CC Private Equity Partners were joined by returning shareholder Bachem Holding AG. The company will use the proceeds to move its Phase I hepatitis C and breast cancer vaccines into Phase II trials, and to advance its preclinical RSV and Candida vaccines into human studies.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies